JPMORGAN CHASE & CO - ARBUTUS BIOPHARMA CORP ownership

ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 71 filers reported holding ARBUTUS BIOPHARMA CORP in Q2 2018. The put-call ratio across all filers is 0.38 and the average weighting 0.1%.

Quarter-by-quarter ownership
JPMORGAN CHASE & CO ownership history of ARBUTUS BIOPHARMA CORP
ValueSharesWeighting
Q3 2023$241,570
-0.0%
119,000
+13.3%
0.00%
Q2 2023$241,641
-72.9%
105,061
-64.3%
0.00%
Q1 2023$891,210
+524141.2%
294,165
+303.8%
0.00%
Q4 2022$170
-99.9%
72,844
+4.5%
0.00%
Q3 2022$133,000
-23.1%
69,734
+8.6%
0.00%
Q2 2022$173,000
-1.1%
64,191
+8.9%
0.00%
Q1 2022$175,000
+5.4%
58,926
+37.9%
0.00%
Q4 2021$166,000
+3.1%
42,737
+13.6%
0.00%
Q3 2021$161,000
+53.3%
37,611
+8.6%
0.00%
Q2 2021$105,000
-10.3%
34,626
-1.4%
0.00%
Q1 2021$117,00035,112
+97433.3%
0.00%
Q4 2020$036
+9.1%
0.00%
Q2 2020$0
-100.0%
33
-100.0%
0.00%
Q3 2019$145,000
-78.9%
95,146
-68.7%
0.00%
Q2 2019$688,000
-75.3%
304,340
-60.9%
0.00%
-100.0%
Q1 2019$2,784,000
+5952.2%
777,470
+6460.4%
0.00%
Q4 2018$46,000
-95.3%
11,851
-88.6%
0.00%
Q3 2018$979,000
-38.3%
103,628
-52.4%
0.00%
Q2 2018$1,587,000
+42.7%
217,501
-2.2%
0.00%
Q1 2018$1,112,000
+23.8%
222,329
+25.0%
0.00%
Q4 2017$898,000
+969.0%
177,798
+1252.0%
0.00%
Q3 2017$84,000
+250.0%
13,151
+97.3%
0.00%
Q2 2017$24,000
-4.0%
6,666
-12.3%
0.00%
Q1 2017$25,000
+4.2%
7,600
-21.6%
0.00%
Q4 2016$24,000
+300.0%
9,700
+592.9%
0.00%
Q2 2016$6,0001,4000.00%
Other shareholders
ARBUTUS BIOPHARMA CORP shareholders Q2 2018
NameSharesValueWeighting ↓
Two Seas Capital LP 825,569$3,211,0002.46%
GREAT POINT PARTNERS LLC 668,907$2,602,0000.58%
JACOB ASSET MANAGEMENT OF NEW YORK LLC 270,000$1,050,0000.47%
QCM Cayman, Ltd. 10,205$40,0000.24%
Pitti Group Wealth Management, LLC 50,000$195,0000.22%
RTW INVESTMENTS, LP 2,504,493$9,742,0000.14%
Hudson Bay Capital Management LP 1,805,700$7,024,0000.07%
Quinn Opportunity Partners LLC 276,485$1,076,0000.07%
Kepos Capital LP 200,000$778,0000.06%
XTX Topco Ltd 29,026$113,0000.06%
View complete list of ARBUTUS BIOPHARMA CORP shareholders